Brokerages forecast that Recro Pharma Inc (NASDAQ:REPH) will post $16.77 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Recro Pharma’s earnings, with the highest sales estimate coming in at $18.00 million and the lowest estimate coming in at $15.32 million. Recro Pharma reported sales of $17.11 million in the same quarter last year, which would suggest a negative year over year growth rate of 2%. The company is scheduled to report its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $72.73 million for the current financial year, with estimates ranging from $71.00 million to $73.43 million. For the next fiscal year, analysts forecast that the business will report sales of $77.80 million, with estimates ranging from $71.00 million to $88.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Recro Pharma.
Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The firm had revenue of $21.74 million during the quarter, compared to analysts’ expectations of $16.81 million.
A number of large investors have recently bought and sold shares of REPH. Wells Fargo & Company MN increased its holdings in Recro Pharma by 45.4% during the 1st quarter. Wells Fargo & Company MN now owns 76,832 shares of the specialty pharmaceutical company’s stock valued at $846,000 after acquiring an additional 23,984 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Recro Pharma by 130.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 187,364 shares of the specialty pharmaceutical company’s stock valued at $2,063,000 after acquiring an additional 106,095 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Recro Pharma by 211.8% during the 1st quarter. JPMorgan Chase & Co. now owns 98,751 shares of the specialty pharmaceutical company’s stock valued at $1,087,000 after acquiring an additional 67,078 shares in the last quarter. Citadel Advisors LLC purchased a new position in Recro Pharma during the 1st quarter valued at about $126,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Recro Pharma by 6,480.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock valued at $2,595,000 after acquiring an additional 232,130 shares in the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.
Shares of NASDAQ REPH traded down $0.24 during midday trading on Wednesday, hitting $6.96. The company had a trading volume of 245,600 shares, compared to its average volume of 265,322. The company has a quick ratio of 1.42, a current ratio of 1.59 and a debt-to-equity ratio of 2.22. Recro Pharma has a twelve month low of $4.78 and a twelve month high of $13.05. The stock has a market capitalization of $147.30 million, a price-to-earnings ratio of -3.62 and a beta of -0.82.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.